• By Concept
  • By Last Name
  • By Full Text

Kevin J Cullen

Kevin J Cullen

School of Medicine

Medicine

School of Medicine

Program in Oncology

School of Medicine

Pharmacology and Experimental Therapeutics

 BiomedExperts Profile

Directory linkout


Help us refine your profile

Publication Detail

The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.



Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.

M R Posner; J H Lorch; O Goloubeva; M Tan; L M Schumaker; N J Sarlis; R I Haddad; K J Cullen (Profiled Authors: Olga Goloubeva; Kevin J Cullen)

The Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY, USA. marshall.posner@mssm.edu
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(5):1071-7.

Abstract

BACKGROUND: The association between human papillomavirus (HPV) and overall survival (OS) in oropharynx cancer (OPC) was retrospectively examined in TAX 324, a phase III trial of sequential therapy for locally advanced head and neck cancer. METHODS: Accrual for TAX 324 was completed in 2003 and data updated through 2008. Pretherapy tumor biopsies were studied by PCR for human papillomavirus type 16 and linked to OS, progression-free survival (PFS) and demographics. RESULTS: Of 264 patients with OPC, 111 (42%) had evaluable biopsies; 56 (50%) were HPV+ and 55 (50%) were HPV-. HPV+ patients were significantly younger (54 versus 58 years, P = 0.02), had T1/T2 primary cancers (49% versus 20%, P = 0.001), and had a performance status of zero (77% versus 49%, P = 0.003). OS and PFS were better for HPV+ patients (OS, hazard ratio = 0.20, P < 0.0001). Local-regional failure was less in HPV+ patients (13% versus 42%, P = 0.0006); at 5 years, 82% of HPV+ patients were alive compared with 35% of HPV- patients (P < 0.0001). CONCLUSIONS: HPV+ OPC has a different biology compared with HPV- OPC; 5-year OS, PFS, and local-regional control are unprecedented. These results support the possibility of selectively reducing therapy and long-term morbidity in HPV+ OPC while preserving survival and approaching HPV- disease with more aggressive treatment.

Scientific Context

This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.

Related Publications